ATE476502T1 - Recombinant modifiziertes plasmin - Google Patents

Recombinant modifiziertes plasmin

Info

Publication number
ATE476502T1
ATE476502T1 AT05737862T AT05737862T ATE476502T1 AT E476502 T1 ATE476502 T1 AT E476502T1 AT 05737862 T AT05737862 T AT 05737862T AT 05737862 T AT05737862 T AT 05737862T AT E476502 T1 ATE476502 T1 AT E476502T1
Authority
AT
Austria
Prior art keywords
domain
recombinant modified
terminal
human plasminogen
polypeptide
Prior art date
Application number
AT05737862T
Other languages
English (en)
Inventor
Jennifer Hunt
Valery Novokhatny
Original Assignee
Talecris Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE476502(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Talecris Biotherapeutics Inc filed Critical Talecris Biotherapeutics Inc
Application granted granted Critical
Publication of ATE476502T1 publication Critical patent/ATE476502T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05737862T 2004-04-22 2005-04-21 Recombinant modifiziertes plasmin ATE476502T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56447204P 2004-04-22 2004-04-22
PCT/US2005/013562 WO2005105990A2 (en) 2004-04-22 2005-04-21 Recombinantly modified plasmin

Publications (1)

Publication Number Publication Date
ATE476502T1 true ATE476502T1 (de) 2010-08-15

Family

ID=34982338

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05737862T ATE476502T1 (de) 2004-04-22 2005-04-21 Recombinant modifiziertes plasmin

Country Status (27)

Country Link
US (2) US8034913B2 (de)
EP (2) EP1740698B1 (de)
JP (1) JP5026254B2 (de)
KR (1) KR101161819B1 (de)
CN (2) CN1961070A (de)
AT (1) ATE476502T1 (de)
AU (1) AU2005238464B2 (de)
BR (1) BRPI0510063B8 (de)
CA (1) CA2563675C (de)
CY (1) CY1111650T1 (de)
DE (1) DE602005022692D1 (de)
DK (1) DK1740698T3 (de)
EA (1) EA010784B1 (de)
ES (2) ES2349555T3 (de)
HR (1) HRP20100568T1 (de)
IL (1) IL178343A (de)
MA (1) MA28590B1 (de)
MX (1) MXPA06012236A (de)
NO (1) NO338542B1 (de)
NZ (1) NZ550250A (de)
PL (2) PL1740698T3 (de)
PT (2) PT2246417E (de)
RS (1) RS51623B (de)
SI (1) SI1740698T1 (de)
TN (1) TNSN06332A1 (de)
WO (1) WO2005105990A2 (de)
ZA (1) ZA200608498B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2394103C2 (ru) 2004-02-11 2010-07-10 Биолекс Терапьютикс, Инк. Экспрессия плазминогена и микроплазминогена в ряске
NZ550250A (en) 2004-04-22 2009-05-31 Talecris Biotherapeutics Inc Recombinantly modifed plasminogen
US8231869B2 (en) * 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
JP5539896B2 (ja) * 2007-11-29 2014-07-02 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
NZ589557A (en) 2008-06-04 2012-08-31 Talecris Biotherapeutics Inc Immobilised streptokinase, method and kit for preparing plasmin
ES2552337T3 (es) 2009-03-03 2015-11-27 Grifols Therapeutics Inc. Procedimientos para la preparación de plasminógeno
US9226953B2 (en) 2009-07-10 2016-01-05 Thrombogenics Nv Variants of plasminogen and plasmin
EP2480249B1 (de) 2009-08-28 2015-01-28 ThromboGenics N.V. Plasmin zur Behandlung von Filtrationsfehlern nach Trabeculektomie
RU2432397C2 (ru) * 2009-11-24 2011-10-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД СО СВОЙСТВАМИ ПЛАЗМИНОГЕНА ЧЕЛОВЕКА ПРЕВРАЩАТЬСЯ ПРИ АКТИВАЦИИ В ПЛАЗМИН, КОТОРЫЙ КАТАЛИЗИРУЕТ РАСЩЕПЛЕНИЕ ФИБРИНА, ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ПОЛИПЕПТИД, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДА И ТРАНСФОРМИРОВАННАЯ КЛЕТКА Escherichia coli - ПРОДУЦЕНТ ПОЛИПЕПТИДА
RU2432396C2 (ru) * 2009-11-24 2011-10-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД СО СВОЙСТВАМИ ПЛАЗМИНОГЕНА ЧЕЛОВЕКА ПРЕВРАЩАТЬСЯ ПРИ АКТИВАЦИИ В ПЛАЗМИН, КОТОРЫЙ КАТАЛИЗИРУЕТ РАСЩЕПЛЕНИЕ ФИБРИНА, ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ПОЛИПЕПТИД, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДА И ТРАНСФОРМИРОВАННАЯ КЛЕТКА Escherichia coli - ПРОДУЦЕНТ ПОЛИПЕПТИДА
ES2583082T3 (es) 2011-01-05 2016-09-19 Thrombogenics N.V. Variantes de plasminógeno y plasmina
RU2604810C2 (ru) 2011-08-12 2016-12-10 Тромбодженикс Н.В. Варианты плазминогена и плазмина
US10709771B2 (en) * 2015-12-18 2020-07-14 Talengen International Limited Method for preventing or treating diabetic retinopathy
WO2018107690A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法
CN108210902A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪肝的药物及其用途
WO2018107703A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种促进胰岛β细胞损伤修复和减少胰岛纤维化的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
CA3182911A1 (en) * 2020-05-11 2021-11-18 Talengen International Limited Method and drug for treating spinal muscular atrophy
JP2023550301A (ja) 2020-11-25 2023-12-01 グリフォルス・ワールドワイド・オペレーションズ・リミテッド 創傷治癒
US11964004B2 (en) * 2021-03-31 2024-04-23 Shenzhen Bay Laboratory Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof
AU2023309803A1 (en) 2022-07-22 2025-01-09 Grifols Worldwide Operations Limited Stable plasmin compositions for organ preservation and reconditioning
WO2025235230A1 (en) * 2024-05-07 2025-11-13 The Scripps Research Institute Engineered plasmin molecules and related compositions for treating thrombosis
CN119331857B (zh) * 2024-12-19 2025-05-16 南通大学 一种新型重组蛋白Plasminogen-CTM及应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5149533A (en) * 1987-06-04 1992-09-22 Zymogenetics, Inc. Modified t-PA with kringle-/replaced by another kringle
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
DK0835939T3 (da) 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
CN1163619C (zh) 1996-01-23 2004-08-25 佳根基因组学公司 测定核酸分子序列的方法和组合物
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
JPH10158300A (ja) 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
EP1000176A1 (de) 1997-07-22 2000-05-17 Rapigene, Inc. Computerverfahren und system zum vergleichen von sequenzdaten mit ms
US6538103B1 (en) 1998-07-14 2003-03-25 Bristol--Myers Squibb Company Lysine binding fragments of angiostatin
DE69934595T2 (de) 1998-09-29 2007-10-04 Leuven Research & Development V.Z.W. Verwendung von verbindungen,die alpha2-antiplasmin in vivo reduzieren,zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
AU2001275091A1 (en) 2000-06-02 2001-12-17 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
ATE378413T1 (de) 2000-12-21 2007-11-15 Thromb X N V Hefeexpressionsvektor und verfahren zur herstellung eines rekombinanten proteins durch expression in einer hefezelle
AU2002357249A1 (en) 2001-12-13 2003-07-09 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US20050124036A1 (en) 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
NZ550250A (en) 2004-04-22 2009-05-31 Talecris Biotherapeutics Inc Recombinantly modifed plasminogen
US8231869B2 (en) 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
JP5539896B2 (ja) 2007-11-29 2014-07-02 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン

Also Published As

Publication number Publication date
EA010784B1 (ru) 2008-10-30
PL1740698T3 (pl) 2011-01-31
DK1740698T3 (da) 2010-10-25
WO2005105990A3 (en) 2006-01-12
EP2246417A1 (de) 2010-11-03
IL178343A (en) 2010-11-30
JP5026254B2 (ja) 2012-09-12
EP1740698A2 (de) 2007-01-10
US20110318812A1 (en) 2011-12-29
HK1175812A1 (en) 2013-07-12
BRPI0510063A (pt) 2008-03-11
NO338542B1 (no) 2016-09-05
AU2005238464A1 (en) 2005-11-10
CA2563675A1 (en) 2005-11-10
SI1740698T1 (sl) 2010-11-30
IL178343A0 (en) 2007-02-11
EP1740698B1 (de) 2010-08-04
ES2534744T3 (es) 2015-04-28
ES2349555T3 (es) 2011-01-05
WO2005105990A2 (en) 2005-11-10
HK1099341A1 (en) 2007-08-10
US20100304465A1 (en) 2010-12-02
BRPI0510063B1 (pt) 2020-03-17
US8420079B2 (en) 2013-04-16
BRPI0510063B8 (pt) 2021-05-25
CA2563675C (en) 2012-08-28
US8034913B2 (en) 2011-10-11
JP2007533327A (ja) 2007-11-22
HRP20100568T1 (hr) 2010-11-30
TNSN06332A1 (en) 2008-02-22
ZA200608498B (en) 2008-07-30
EA200601950A1 (ru) 2007-02-27
PL2246417T3 (pl) 2015-06-30
NZ550250A (en) 2009-05-31
DE602005022692D1 (de) 2010-09-16
RS51623B (sr) 2011-08-31
NO20065050L (no) 2006-11-03
MXPA06012236A (es) 2007-01-31
HK1150242A1 (en) 2011-11-11
CN1961070A (zh) 2007-05-09
KR101161819B1 (ko) 2012-07-03
AU2005238464B2 (en) 2011-01-27
KR20070006918A (ko) 2007-01-11
EP2246417B1 (de) 2015-01-21
CN102660564B (zh) 2013-05-08
CY1111650T1 (el) 2015-10-07
PT1740698E (pt) 2010-11-02
MA28590B1 (fr) 2007-05-02
CN102660564A (zh) 2012-09-12
PT2246417E (pt) 2015-05-05

Similar Documents

Publication Publication Date Title
CY1111650T1 (el) Ανασυνδυαστικα τροποποιημενη πλασμινη
NZ593837A (en) Recombinantly modified plasmin
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
MX2007001345A (es) Regiones variantes fc.
EA200901430A1 (ru) Варианты фермента аспарагиназы и их применение
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
NZ601094A (en) Modified cry1ca insecticidal cry proteins
NZ588200A (en) Procoagulant peptides
ATE463512T1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
ATE548380T1 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
ATE277172T1 (de) Rekombinante blutgerinnungsproteasen
Hahn et al. Purification and characterization of a serine protease with fibrinolytic activity from Tenodera sinensis (praying mantis)
TW200733970A (en) Recombinantly modified plasmin
WO2005078109A3 (en) Expression of plasminogen and microplasminogen in duckweed
Castro et al. Current status of snake venom thrombin-like enzymes
DE60336265D1 (de) Inhibitoren der enzymaktivität der endooligopeptidase a (eopa) und ihre verwendungen
NO20082864L (no) Nytt polypeptid med esteraseaktivitet og rekombinant esterase samt anvendelse derav
WO2005037202A3 (en) Methods for modulating angiogenesis
Amoozegari et al. Purification of blood coagulation factor V activator from the venom of Iranian Vipera lebetina.
WO2003085377A3 (en) Novel pancortin-pablo protein interactions and methods of use thereof
ATE460476T1 (de) Menschliche protein phosphatase mit ef-hände-1 (ppef-1)- ähnliches genvariant assoziert mit t- zellen lymphoblastisches lymphom

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1740698

Country of ref document: EP